Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
21 oct. 2021 08h30 HE
|
Silence Therapeutics plc
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication...
Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference
01 oct. 2020 07h00 HE
|
Silence Therapeutics plc
Silence Therapeutics to Participate in the Chardan Virtual 4th Annual Genetic Medicines Conference 1 October 2020 LONDON, Silence Therapeutics plc (AIM: SLN) and (Nasdaq: SLN) (“Silence” or “the...